Summit Therapeutics (NASDAQ:SMMT) announced that data for its novel investigational bispecific antibody, ivonescimab, will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego, CA. The data was generated and analyzed in collaboration with Akeso, Inc. Ivonescimab, known as SMT112 in the United States, Canada, Europe, and Japan, and as AK112 in China and Australia, combines the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Summit has begun its clinical development of ivonescimab in two proposed NSCLC indications.